Although targeting glutamine metabolism in RCC is a promising therapeutic strategy, there are no imaging techniques available to identify the patients most likely to respond to GLS inhibition and no methods to rapidly assess response to GLS inhibitors. This evidence concerns the gene GLS and renal cell carcinoma.